Phase I Trial of the Combination of Docetaxel, Prednisone, and Pasireotide in Metastatic Castrate-Resistant Prostate Cancer

The safety and efficacy of the additional use of the novel agent pasireotide with the standard regimen of docetaxel and prednisone was explored in patients with metastatic prostate cancer. The results showed tolerability and preliminary efficacy. The combination is worthy of future investigation in...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Clin Genitourin Cancer
Huvudupphovsmän: Thakur, Manish K., Heilbrun, Lance, Dobson, Kimberlee, Boerner, Julie, Stark, Karri, Li, Jing, Smith, Daryn, Heath, Elisabeth, Fontana, Joseph, Vaishampayan, Ulka
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2018
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6136146/
https://ncbi.nlm.nih.gov/pubmed/29534939
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clgc.2018.01.019
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk